Table 2 The association of TMB levels and clinical status.
From: Molecular profiles and tumor mutational burden analysis in Chinese patients with gynecologic cancers
TMB, median (range), mutations/Mb | P valuea | TMB level | P valueb | |||
|---|---|---|---|---|---|---|
Low (%) | Moderate to high (%) | |||||
Age, median (range), years | 0.04 | 0.26 | ||||
<40 | 14 | 0 (0–4.80) | 13 (92.86%) | 1 (7.14%) | ||
>=40 | 103 | 0.67 (0–41.45) | 83 (80.58%) | 20 (19.42%) | ||
Site of Disease | 0.81 | 0.11 | ||||
Ovary (include primary peritoneal and fallopian tube) | 68 | 0.36 (0–22.26) | 60 (88.24%) | 8 (11.76%) | ||
Cervix | 32 | 0.67 (0–40.81) | 23 (71.87%) | 9 (28.13%) | ||
Endometrial | 17 | 2.30 (0–41.45) | 13 (76.47%) | 4 (23.53%) | ||
stage | 0.001c | 0.03 | ||||
Stage I | 21 | 0 (0–3.20) | 21 (100%) | 0 (0%) | ||
Stage II | 34 | 0 (0–4.80) | 30 (88.24%) | 4 (11.76%) | ||
Stage III | 43 | 0.83 (0–22.26) | 34 (79.07%) | 9 (20.93%) | ||
Stage IV | 15 | 2.92 (0–41.45) | 8 (53.33%) | 7 (46.67%) | ||
NA | 4 | 2.62 (0.45–13.80) | 3 (75%) | 1 (25%) | ||
HPV status (Cervix cancer) | 0.506 | 0.255 | ||||
positive | 9 | 0 (0–9) | 7 (77.78%) | 2 (22.22%) | ||
negative | 5 | 2 (0–7) | 5 (100%) | 0 (0%) | ||
uncertain | 18 | 2.28 (0–40.81) | 11 (61.11%) | 7 (38.89%) | ||
Subtype of Endometrial Carcinoma | — | — | ||||
Type I | 16 | 2.30 (0–41.45) | 12 (75%) | 4 (25%) | ||
Type II | 1 | 0.95 | 1 (100%) | 0 (0%) | ||
Tissue types | 0.34 | 0.18 | ||||
Serous adenocarcinoma | 60 | 0.36 (0–22.26) | 52 (86.67%) | 8 (13.33%) | ||
Clear cell adenocarcinoma | 3 | 0.38 (0–3.20) | 3 (100%) | 0 (0%) | ||
Endometroid adenocarcinoma | 17 | 2.30 (0–41.45) | 13 (76.47%) | 4 (23.53%) | ||
Squamous cell carcinoma | 31 | 0.99 (0–40.81) | 22 (70.97%) | 9 (29.03%) | ||
Mucinous adenocarcinoma | 1 | 0 | 1 (100%) | 0 (0%) | ||
Other | 5 | 0 (0–2.30) | 5 (100%) | 0 (0%) | ||
